Johnson & Johnson reported fourth-quarter figures that topped consensus
In Q4, JNJ had an adjusted EPS of $1.86, slightly higher than the $1.82 per share expected. At the same time, the company generated revenues of $22.48 billion, while the market was looking for $21.67 billion.
Much of its revenue came from the pharmaceutical business, which produces the COVID-19 vaccine. The division reported revenues of $12.26 billion, 16% higher than that reported in Q4 2019.
For the future, Johnson & Johnson expects an adjusted EPS between $9.40-$9.60, and sales to reach a high of $91.7 billion. Moreover, as early as next week, the company is expected to publish data from Phase III of its COVID-19 vaccine trial.
Both US officials and Wall Street are looking forward to the vaccine to receive FDA’s approval. #JNJ’s vaccine requires just one dose to be administrated, unlike Moderna’s and Pfizer’s, which requires two doses.
Following the news, Johnson & Johnson stock price gained 2% in today’s premarket session.
Stay updated with the latest earning reports with CAPEX.com!
Users/readers should not rely solely on the information presented herewith and should do their own research/analysis by also reading the actual underlying research. The content herewith is generic and does not take into consideration individual personal circumstances, investment experience or current financial situation.
Therefore, Key Way Investments Ltd shall not accept any responsibility for any losses of traders due to the use and the content of the information presented herein. Past performance is not a reliable indicator of future results.